Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 12/20 | 0.46 |
| ▸ | F2 | P00734 | 10/20 | 0.46 |
| ▸ | F10 | P00742 | 10/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.46 |
| ▸ | F3 | P13726 | 4/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.46 |
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5882810 | 0.89 | F10 (0.39) | F7F2F10PRSS1F3 | |
| SCHEMBL5883266 | 0.84 | F7 (0.47) | F7F2F10PRSS1F3 | |
| SCHEMBL5883704 | 0.83 | F7 (0.61) | F7F2F10PRSS1F3 | |
| SCHEMBL5883271 | 0.80 | CYP1A2 (0.47) | — | |
| SCHEMBL5883292 | 0.76 | F10 (0.47) | F7F2F10PRSS1F3 | |
| SCHEMBL5882700 | 0.76 | F10 (0.52) | F7F2F10PRSS1F3 | |
| SCHEMBL5882689 | 0.74 | F10 (0.66) | F7F2F10PRSS1F3 | |
| SCHEMBL5882705 | 0.74 | F10 (0.66) | F7F2F10PRSS1F3 | |
| SCHEMBL5883415 | 0.74 | F10 (0.66) | F7F2F10PRSS1F3 | |
| SCHEMBL5883297 | 0.73 | KMT2A (0.46) | F7F2F10PRSS1F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071212-B2 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | F7 1019/4885F2 371/4885F10 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.